Daiichi Sankyo (4568.T)

Executive Summary

Daiichi Sankyo has transformed into a global oncology powerhouse, driven by its proprietary DXd antibody-drug conjugate (ADC) technology platform. With blockbusters like Enhertu (trastuzumab deruxtecan) and a deep pipeline targeting HER2, TROP2, HER3, and more, the company is pioneering next-generation ADCs that address high unmet needs across multiple tumor types. Its strong clinical data and regulatory momentum have positioned it as a leader in precision oncology, with several pivotal readouts and approvals anticipated in the near term. Looking ahead, Daiichi Sankyo's pipeline catalysts are set to reinforce its growth trajectory. Key upcoming events include regulatory decisions for patritumab deruxtecan in EGFR-mutant non-small cell lung cancer (NSCLC) and datopotamab deruxtecan in breast cancer. Meanwhile, expansion of Enhertu into earlier treatment lines could significantly broaden its addressable market. With a robust balance sheet and strategic partnerships (e.g., with AstraZeneca), Daiichi Sankyo is well-positioned to maintain its competitive edge and deliver sustained value to shareholders.

Upcoming Catalysts (preview)

• Q4 2026Patritumab deruxtecan (HER3-DXd) FDA decision in EGFR-mutant NSCLC after progression on prior therapy75% success
• H2 2026Datopotamab deruxtecan (Dato-DXd) regulatory submission for HR+/HER2- advanced breast cancer (TROPION-Breast01)80% success
• Q1 2027Enhertu Phase 3 readout in first-line HER2-low advanced breast cancer (DESTINY-Breast09)70% success